Agathos Biologics Appoints Jagadish Loganathan, Ph.D., to Lead Research and Development
Press release
May 26, 2021 (FARGO, N.D.) – Agathos Biologics, a biotechnology company developing transformational science in biomanufacturing, biologic payload delivery, and cell and gene therapy within a strong ethical and moral framework, today announced the appointment of Jagadish Loganathan, Ph.D. as Director, Research and Development. Loganathan’s responsibilities include establishing research and development operations at Agathos’ Fargo, North Dakota facilities, recruiting and managing scientific staff, and leading internal and external programs.
Prior to joining Agathos Loganathan was a Scientist at the Indiana University School of Medicine where he studied the importance of the correct compartmentalization of different molecular signals mediated by natural compounds targeting cancer genes. His scientific experience includes work as a research associate at North Dakota State University (NDSU) targeting cancer cells in a hypoxic environment using nanoparticles and the molecular mechanism and pathophysiology of bronchial asthma in the different sexes. Previously as a postdoctoral fellow at NDSU he studied the chemotherapeutic effects of plant-derived small molecules and lentiviral vectors on pancreatic and lung cancer cells. Loganathan received his Ph.D. in microbiology from the University of Madras in Chennai, India.
“We are pleased to have Jagadish join Agathos during this critical time as we build our research and development capabilities and team,” said James Brown, CEO. “His accomplishments and experience in molecular biology, cell culture, and microbiology will enable him to effectively lead our efforts to develop new materials and methods for biomanufacturing and use them in our therapeutic programs.”
“I am excited to bring my skills and expertise to Agathos Biologics and pursue our mission as the good science company,” said Loganathan. “Our novel biomanufacturing and therapeutic products will provide scientific and medical benefits without ethical concerns about the origin or source of materials used in their development. I look forward to using my experiences building laboratory operations and mentoring others to quickly establish Agathos as a leader in ethical biotechnology.”